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Abstract
The objective of this study was to develop a composite buccal wafer 
for protein drug delivery. The polymeric vehicle used in this study combined 
chitosan and sodium alginate with bovine serum albumin (BSA) as a model 
drug. The wafers were obtained by freeze-drying gels of the polymers in well 
plates. Prior to the lyophilisation process, differential scanning calorimetry 
was performed to establish a suitable freeze-drying cycle. Preliminary 
characterization experiments were undertaken to select the optimum composite 
gel containing sodium alginate and chitosan in a 4:1 ratio respectively for drug 
loading. A second series of characterisation tests were performed on the drug-
loaded wafers prepared from gels containing 0.25 and 0.5 % w/w of BSA. The 
formulations were functionally characterised for swelling, mucoadhesive and 
drug dissolution properties. The morphology and crystallinity were investigated 
using a scanning electron microscope and X-ray diffractometer respectively. 
The results from drug dissolution studies over a two-hour period showed 66% 
and 31% cumulative drug release for the wafers obtained from gels containing 
0.25 and 0.50 % w/w BSA respectively. These results show the feasibility of 
developing a sustained delivery system for macromolecules by combining 
chitosan and sodium alginate.
Keywords: Chitosan; Sodium alginate; Bovine serum albumin; Buccal 
delivery; Protein delivery
tissue), palatal, sublingual (floor of the mouth) and gingival areas. The 
sublingual and buccal areas are more useful for drug delivery as they 
are more permeable than any other areas of the mouth and represent 
roughly 60% of the total oral mucosa surface area. Despite having a 
smaller surface area of 100cm2 compared to the GIT and skin; which 
are 350,000cm2 and 20,000cm2 respectively, the oral mucosa is an area 
of significant interest [12]. The buccal mucosa is a highly adaptable 
area and considered useful for controlled drug release. One of its 
characteristics is that damaged tissue only requires a short period of 
time to heal in comparison to other areas [13].
Different active pharmaceutical ingredients with low molecular 
weights (small molecules) have been administered via the buccal route 
including analgesics such as fentanyl citrate, ACE inhibitors such as 
captopril and benzodiazepines such as midazolam [14]. However, the 
administration of macromolecules such as peptides and proteins are 
more challenging due to their large size and presence of charge [2, 
15] and several approaches have been proposed to overcome these 
challenges. Ideal systems contain components such as permeation 
enhancers which can manipulate the site of absorption to enhance 
partitioning of the drug into the mucosal tissue or modification of 
the mucosal surface to increase solubility of the drug which increases 
the concentration gradient to enhance absorption [16]. Other studies 
have been reported which show that peptide drugs such as insulin 
can be transported across the mucosa through the use of enzyme 
inhibitors and bioadhesive polymers such as chitosan [17-20]. 
Sodium alginate, the salt form of alginic acid is a polysaccharide 
composed of 1-4 linked α-L-guluronic and β-D-mannuronic acid 
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Introduction
Mucosal drug delivery has gained interest involving the use of 
bioadhesive formulations to administer drugs via sites in the body 
such as buccal [1-4], nasal [5], wound surfaces [6-7] and vaginal [8] 
mucosa. The intimate contact between the bioadhesive dosage form 
and mucosa is facilitated by physico-chemical interactions which allow 
for an improvement of the drug’s absorption and subsequent increase 
in its bioavailability [9]. The drug carrier system, typically a polymer 
hydrogel, adheres to the mucosa, via a process initiated by hydration 
and swelling which allows interpenetration between the bioadhesive 
polymeric chains and the mucin present on the mucosal membrane, 
resulting in the formation of weak bonds [10]. Mucosal surfaces are 
targeted as they present highly vascularised networks, which allow 
therapeutic delivery whilst avoiding pre systemic circulation (first 
pass metabolism). There are other benefits of mucosal drug delivery 
systems including increased patient compliance as there is no pain 
or risk of choking as for injections and tablets respectively. Drug 
levels remain steady therefore allowing better control; which in turn 
reduces the risk of toxicity, as well as complete utilization of the drug 
administered [11]. 
The lining of the oral cavity comprises the buccal (cheek muscle 
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residues [21] and is widely used in pharmaceutical formulations 
due to its high bioadhesive nature, aqueous solubility and its 
good film forming properties [22]. Chitosan is a weak cationic 
polyaminosaccharide derived from deacetylation of the native 
polymer chitin [23], present in shellfish and discovered 200 years 
ago [24]. Chitosan is composed mainly of (1, 4) linked 2-amino-2- 
deoxy-β-D-glucan [25], and has been developed as a suitable matrix 
for the controlled release of protein or peptide drugs over the last 
two decades [26]. It has been reported that “pH sensitive hydrogels 
such as sodium alginate and chitosan are useful for protein delivery 
because of the immunogenicity of most synthetic polymers and the 
requirement for a harsher environment which may denature and 
inactivate the protein” [27]. Formulation of protein based systems 
using both alginate and chitosan as matrices can be achieved under 
relatively mild environments, therefore avoids potential damage to 
the proteins’ native structure. 
Formulations combining sodium alginate and chitosan have been 
reported including particulate systems (e.g. micro and nanoparticles) 
[28, 29] and tablets [30]. These formulations have mainly been 
used for small molecules or delivery via sites other than the buccal 
mucosa. To the best of our knowledge, no study has been reported 
of freeze-dried wafers combining both sodium alginate and chitosan 
for protein or peptide delivery via the buccal mucosa. Though similar 
studies have reported on buccal formulations for protein and peptide 
delivery, these have involved single polymers, mainly chitosan or its 
derivatives [4, 11, 15, 18, 19, 20]. Shaikh and co-workers reported 
that increasing the amount of chitosan in a composite mucoadhesive 
tablet formulation resulted in more controlled drug (itraconazole) 
release while an increase in sodium alginate resulted in improved 
adhesive properties of the tablet [30].
The aim of this study therefore, was to develop a lyophilised 
wafer as a controlled buccal delivery system for protein drugs using 
a combination of sodium alginate and chitosan as the polymeric 
matrices. Bovine serum albumin (BSA) was used as a model drug as 
it is a naturally occurring protein. The wafers have been characterised 
using various analytical techniques to evaluate the wafer’s functional 
physical and mechanical properties. 
Materials and Methods
Materials 
Chitosan (medium molecular weight, 75–85% deacetylated), 
sodium alginate, bovine serum albumin (BSA), Bradford’s reagent, 
mucin from porcine and gelatine were all purchased from Sigma-
Aldrich, Gillingham, UK. Sodium di hydrogen orthophosphate 
dihydrate; acetic acid, sodium hydroxide pellets were all purchased 
from Fisher Scientific (UK).
Pre-formulation studies 
Gel formulation optimization
Initial studies involved development of polymer gels to identify 
an optimum formulation for drug loading. Sodium alginate (SA) 
polymer gels were prepared at concentrations of 0.25% 0.5% and 
1% w/w in distilled water with magnetic stirring at a temperature of 
37°C. Chitosan (Ch) polymer gels were also prepared in the same way 
at the same concentrations but replacing distilled water with acetic 
acid solution (0.05 - 1% v/v). To obtain optimum amounts of both 
polymers in a composite system (1% w/w solution), different ratios of 
each polymer were combined to give a total polymer weight of 0.5 g 
in 50ml of solution as shown in Table 1. The required amount of SA 
was dissolved in 25ml of distilled water (37°C) with stirring followed 
by the addition of 25ml of dilute acetic acid solution (0.05 – 1% v/v) 
after which the required amount of Ch was added. The pH of the final 
composite gels ranged between 4 and 5. Based on the previous criteria, 
the gel with SA: Ch ratio 4:1 was chosen as the ideal combination 
and loaded with two different concentrations of BSA (0.25 and 0.50% 
w/w). Different quantities (1-5 g) of the above gels were poured into 
separate wells of 24 well plates prior to freeze-drying to produce 
wafers with different thickness. 
Differential scanning calorimetry (DSC)
Prior to freeze-drying, pure polymers and combined gel (SA: Ch 
4:1) were analysed using DSC based on a previously reported method 
[11]. The gels were cooled in 40 µl aluminum pans with pierced lids 
from 25 to −55°C at a rate of 10°C/min. They were then re-heated 
back to 25°C at a rate of 20°C/min and the cycle repeated three times.
Freeze-drying
The freeze-drying procedure involved a 3-stage process: freezing, 
primary drying and secondary drying on an Advantage Plus Freeze-
Drying Machine (Biopharma Processing Systems, UK) over a 48 hour 
period using an automated cycle previously reported by Kianfar and 
co-workers [3]. The wafers were removed from the machine and 
immediately placed in sealed plastic envelopes and stored over silica 
gel at room temperature until required.
Functional physical-mechanical characterisation
The wafers were characterised for functional properties essential 
for an effective buccal mucosa protein delivery system as described 
below.
Hardness testing 
The resistance of the wafers to compressive deformation 
(‘hardness’) was measured with the help of a texture analyzer machine 
(Stable Microsystems, UK) in compression mode, using a 6mm (P6) 
cylindrical probe. The test allows assessment of the structural integrity 
of the wafer as whole by applying a known force across the diameter 
BLANK GELS
Polymer ratios
SA: Ch
SA
(mg)
Ch
(mg)
1:4 100.5 400.5
2:3 200.8 300.8
3:2 300.7 200.5
4:1 400.7 100.4
DRUG LOADED GELS
BSA 
concentration
(w/w)
SA
(mg)
Ch
(mg)
BSA
(mg)
0.50 400.2 100.4 250.9
0.25 400.5 100.2 125.3
Table 1: Composition of blank combined gels containing sodium alginate 
(SA) and chitosan (Ch) in different ratios with total polymer concentration of 
1% w/w and drug loaded gels with SA:Ch ratio of 4:1 containing two different 
concentrations of BSA (0.25% w/w and 0.5% w/w).
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of the wafer. The experimental procedure employed was modified 
from a method previously reported [33]. The settings used were pre- 
test speed 0.5mm/s, test speed 0.5mm/s, post-test speed 1.0mm/s 
applied force 100g, contact time 5.0sec, trigger type auto and trigger 
force set a 5.0g. Each wafer obtained by pouring different amounts of 
gel (1-5g) was assessed at three triangulated points and the average 
resistance to compression values computed. 
Swelling capacity 
The swelling capacity allowed for the assessment of the hydration 
capabilities. A phosphate buffered saline (PBS) solution was prepared 
by mixing sodium di hydrogen orthophosphate dehydrate and 
sodium hydroxide in known amounts in distilled water. The pH of 
the PBS solution was adjusted to 6.8± 0.1 and kept at 37°C ± 1°C to 
simulate conditions found in the oral cavity. To further mimic the 
conditions in the mouth 0.5g of mucin was added to obtain a 0.01% 
mucin solution. Each wafer was placed in a weighing boat and the 
weight of the wafer was recorded prior to commencing the test. The 
procedure involved adding 10ml of the PBS based mucin solution to 
each weighing boat. The swelling behavior was recorded over a period 
of 20min at set intervals of 2min, 5min, 10min, 15min and 20min. 
At each time point, the samples were blotted to remove excess liquid 
droplets, weights recorded then a further 10ml of PBS solution added. 
This was repeated for each wafer prepared above and the swelling 
capacity calculated using the following equation
Swelling capacity (%) = 100 x (Xi –X) /X............. equation 1
Where Xi is the weight of the hydrated wafer, and X is the initial 
weight of wafer.
Scanning electron microscopy (SEM)
To the assess the surface topography of the wafers, sliced sections 
were cut from each wafer and placed on double sided adhesive carbon 
tape which had been stuck to stainless steel stubs. The samples were 
sputter coated for 2min at 25mA and 1kV with chromium (EmiTECH 
K575X Sputter Coater, Quorum Technologies Ltd, Kent, UK) 
and placed in the chamber of a Hitachi SU8030 scanning electron 
microscope (Hitachi, Krefeld, Germany). SEM images were acquired 
at an accelerating voltage of 20kV and working distance of 15mm and 
processed with i-scan2000 software [19]. This test was performed for 
different blank wafers obtained from pouring 1g, 2g and 3g of gel as 
well as the two drug loaded wafers.
Mucoadhesion
 To assess how the wafers would adhere to the buccal area, in 
vitro mucoadhesive measurements were performed using a texture 
analyzer (Stable Microsystems, UK). A model buccal mucosal 
substrate was prepared from gelatin gel (6.67% w/v) [11]. 6.67g of 
gelatin was dissolved in 100ml of distilled water. This was heated at 
60°C ± 1°C for a period of 15min. 20ml of the gelatin solution was 
poured into a Petri dish and allowed to solidify. A 2% mucin solution 
was made by dissolving 0.2g of mucin in 10ml of PBS solution (pH 
6.8± 0.1). 500µl of the mucin solution was spread across the solidified 
gelatin gel surface to simulate the buccal mucosa lining. Double-
sided adhesive tape was applied to a P35 adhesive probe and the 
wafer attached to the other side of the tape. The Petri dish was placed 
on the instrument platform and the probe was set to just touch the 
model mucosal surface. The following parameters were applied to the 
texture analyzer in tensile mode; pre- test speed 0.5mm/s, test speed 
0.5mm/s, post-test speed 1.0mm/s applied force 100g, contact time 
60.0s, trigger type auto and trigger force set a 5.0g. The maximum 
force required to detach the wafer from the model mucosal surface, 
referred to as the peak adhesive force (PAF) was measured. The test 
was performed on blank wafers obtained from pouring 2 and 3 g of 
gel as well as the drug loaded wafers (n = 4). 
X-ray diffraction (XRD) 
This test was performed to investigate the physical form 
(crystalline or amorphous) of the blank and drug loaded wafers using 
an X-ray diffractometer (Bruker, Coventry, UK) in transmission 
mode. For the pure polymers, a small amount was spread onto a clear 
film after which it was inserted into a sample holder. In the case of 
the wafers however, the samples were compressed from their original 
width of 2-3mm to 0.5mm using clean glass slides, after which they 
were placed in the sample holder. Diffractograms were acquired for 
each sample over a 2 theta range of 3 - 55°. 
In vitro drug dissolution studies
This test was performed to assess the drug releasing profile of 
the BSA from the two drug loaded formulations. Prior to dissolution 
studies, calibration solutions (0.01 – 0.05 mg/ml) of BSA were used 
to plot a calibration curve using Bradford assay. 1ml of each solution 
was placed in a cuvette followed by the addition of 2ml of Bradford’s 
reagent. The absorbance was measured at 595nm for each dilution. 
This was possible as the binding of BSA to the dye present in the 
reagent results in a shift from the reddish-brown colour to a deep blue 
colour. The dissolution study required the use of the Franz diffusion 
cell apparatus. The wafer was placed in the donor compartment of 
the Franz cell on a wire mesh used as a membrane and the receptor 
compartment was filled with PBS (pH 6.8±0.1) solution until it just 
touched the wire gauze and the water jacket was filled with distilled 
water. The apparatus was placed on a heated magnetic stirrer and kept 
at 37°C. At set intervals of 15, 30, 45, 60, 90 and 120 min, 1ml aliquots 
were removed and placed in plastic tubes. To maintain a consistent 
volume, 1ml of buffer solution was added after withdrawal of each 
aliquot. Each sampled aliquot was then treated with 2ml Bradford’s 
reagent and absorbance measured at 595nm. The calibration curve 
was used to calculate the concentration of BSA at each sample time 
point, and used to plot a graph of percentage drug release against 
time.
Results and Discussion
Pre-formulation studies 
Ideal gels (1% w/w) were selected on the basis of ease of pouring 
and homogeneity with no lumps of undissolved polymer. Preliminary 
investigations involved the use of different concentrations of acetic 
acid (0.05%, 0.10%, 0.25%, 0.5% and 1%, and v/v) to prepare Ch gels. 
This was due to the fact that unlike SA, Ch which is the deacetylated 
derivative of chitin is insoluble in deionised water. However, it has 
free protonable amino groups present in the D-glucosamine unit in 
its structure which makes it soluble in aqueous acidic conditions and 
also important for some of its known properties [31, 32]. However, 
acetic acid concentration of 1 % w/w posed a potential risk with 
regards to toxicity without removing residual traces. Therefore, the 
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different lower concentrations were used to prepare Ch gels. Based 
on visual observations, it was concluded that all the gels appeared 
similar with complete dissolution of the Ch as shown in Figure 1. 
As a result, the lowest acetic acid concentration (0.05 % v/v) was 
selected for all subsequent gel preparation as that was deemed safest 
for buccal application as well as not requiring the need for any further 
purification step such as membrane dialysis. 
The composite gel comprising SA and Ch in the ratio of 4:1 was 
chosen as the ideal combination as it was free flowing and therefore 
easy to pour and remained clear and transparent. The other combined 
gels were too viscous and easily set to a solid mass, which made 
stirring difficult and also difficult to pour for freeze-drying. This 
increase in viscosity with increasing Ch content could be related to 
electrostatic interactions between the manuronate / guluronate side 
chains (negatively charged) of SA and the protonated amine group 
of Ch which is expected to increase with increasing chitosan content 
resulting in a stronger polymeric gel structure. 
Differential scanning calorimetry (DSC) 
DSC provided vital information such as the glass transition 
and eutectic temperature for the polymeric gels and is summarized 
in Table 2 below. This was important for determining the thermal 
events occurring during thermal treatment (freezing and subsequent 
heating) to determine the optimum conditions for freeze-drying 
(glass transition and eutectic melts), to avoid possible product 
collapse during the primary drying stage.
Freeze drying 
Freeze-drying relies on two principles, temperature and pressure. 
During the freeze-drying process the polymeric gel was first frozen to 
form a solute-ice crystal mixture referred to as freeze-concentrate. In 
the second phase, heat is applied at a low pressure which allows the 
ice crystals in the freeze-concentrate to be sublimated without going 
through the liquid phase. This ensured the water in the polymer was 
completely removed leaving behind a porous matrix in the form of 
a wafer. Generally, the blank and BSA loaded wafers were creamy 
white in appearance and spongy in nature due to the air pockets 
locked within their porous matrix structure. However, addition of 
the BSA made the wafers tougher possibly due to the interaction with 
the polymer. Figure 2 shows digital images of the lyophilised wafers 
prepared from the various gels described above, after the freeze-drying 
process. From visual observation, the wafer obtained by pouring 5g 
of gel was not deemed feasible to be used as a buccal delivery system 
because of relatively large thickness which will make it difficult to 
retain in the cheek region without biting into it. These will most likely 
cause discomfort and reduce patient compliance. On the other hand, 
the wafers obtained from pouring 1 and 2 g of gel were too thin to 
be effective as they will most likely disintegrate rapidly with saliva 
washing. As a result, the wafer obtained from pouring 3g of gel was 
the formulation of choice for drug loading.
Physical characterisation
Hardness Test
Table 3 shows the results from compressing the wafers 
representing the peak resistance force to deformation to a given 
depth of compression. The results for the blank wafers showed a 
gradual increase in hardness with increasing thickness (weight of 
gel poured) though the differences were not marked. The increase 
could relate to relatively higher polymer density with increasing 
weight of gel poured as the higher weights contained more polymer 
(a) (b) (c) (d) (e) (f)
Figure 1: Ch gels produced using different concentrations of acetic acid (a) 
0.05, (b) 0.10, (c) 0.15, (d) 0.25, (e) 0.50 and (f) 1.0 % v/v showing clear 
transparent solutions at each concentration of acetic acid. 
7 Glass transition peak(°C)
Melt peak
(°C)
SA powder 41.54 -
Ch powder - -
SA gel - 4.18
Ch gel - 2.76
SA: Ch 4:1 gel 0.64
Table 2: DSC profiles of major peaks during thermal treatment simulating that 
occurring during freeze-drying.
BLANK
Wafers prepared from pouring 
different weights of gel
Force (N)
1 2 3 Average
1g 2.30 2.42 2.40 2.37
2g 2.62 2.72 2.62 2.65
3g 2.90 2.724 2.83 2.82
5g 2.90 2.94 2.98 2.94
Wafers containing different 
amounts of BSA (% w/w)
DRUG LOADED
1 2 3 Average
0.25 4.30 4.53 4.34 4.39
0.50 6.02 5.47 5.69 5.73
Table 3: Resistance to deformation (hardness) of blank and drug loaded wafers 
prepared from SA:Ch 4:1 gels showing the effect of wafer thickness and BSA 
concentration. The drug loaded wafers were prepared by pouring 3 g of gel.
 
(a) 
 
  
 
SA:Ch 5g SA:Ch 3g SA:Ch 2g SA:Ch 1g 
SA:Ch 4:1, 3g, 0.25% w/w BSA SA:Ch 4:1, 3g, 0.50% w/w BSA (b) 
Figure 2 : (a) Freeze-dried wafers obtained by pouring different weights of 
composite (SA:Ch 4:1) gels showing differences in thickness (b) BSA loaded 
wafers obtained from pouring 3g of SA:Ch 4:1 gels.
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per unit volume of wafer [33] and could well be related to changes 
in porosity, though this requires investigation. The results for the 
drug-loaded wafers show that formulations containing 0.50% w/w 
BSA were stronger than the blank wafers and those containing 
0.25% w/w BSA. Generally, a hardness value between 3 – 6 N is ideal 
[33], however, this is dependent on other factors such as the type 
of polymer used and the intended application. For example, wafers 
meant for rapid release will require a relatively low hardness value 
to allow rapid hydration, disintegration and subsequent drug release. 
For a fixed dose of macromolecule, the hardness could be adjusted 
by changing the total concentration of polymer or by incorporation 
of an appropriate plasticizer. The former will increase the hardness 
value whilst the latter generally decreases the rigidity of the polymer 
matrix with a resultant decrease in hardness. The increase in hardness 
for BSA loaded wafers could also be due to the interaction between 
the protein and the two polymers used. The possible interactions 
may vary between the polymers (SA or Ch) and the BSA and also 
complicated by the interaction between the two polymers themselves. 
For example, the amine functionality of Ch and hydroxyl groups 
of both SA and Ch can couple with the BSA [34]. Hydrophobic 
interactions between the non polar regions of the polymers and the 
BSA might also be possible. Strong charge to charge interactions 
have also been demonstrated between proteins and Ch and known to 
affect some of its physical characteristics [35]. However, these require 
further investigation to determine the specific interactions involved. 
Swelling Capacity 
Figure 3a shows the swelling profiles for blank wafers prepared 
by pouring 1, 2, 3 and 5 g of the combined gel (SA: Ch 4:1). From 
the results, it can be observed that all of the blank wafers reached full 
saturation in 5 min, and the downward profile after 5 min represents 
the gradual erosion of the wafers. The wafers obtained from pouring 
1g and 2g of gel reduced significantly in weight after 15min. This 
suggests that at 15min, the wafer began to completely disintegrate 
corresponding to the loss of structural integrity. However, the wafer 
obtained from pouring 5g of gel retained its structural integrity owing 
to the slower rate of hydration and swelling, due to the presence of 
higher amount of total polymer within the same volume of matrix. 
The drug loaded wafers reached saturation in 2min, but unlike the 
blank wafers, the swelling capacity remained fairly constant implying 
that the drug loaded wafers maintained their structural integrity over 
a longer time period, and lost minimal weight in comparison to the 
blank wafers which all showed signs of disintegration. This may be 
due to the bonding between the BSA and the polymer as suggested 
above. Further, the wafers containing higher amounts of BSA showed 
slightly lower swelling but showed a more constant weight loss after 2 
min compared to the 0.25% BSA loaded wafer which showed a much 
more rapid weight reduction after 10min. 
Scanning electron microscopy (SEM)
Figure 4 shows the SEM images for blank and drug loaded wafers 
all showing a porous polymeric network within the wafer matrix. The 
blank wafers obtained from pouring 1g of gel appear to show smaller 
pores that were more uniformly distributed compared to those 
obtained from pouring 2g and 3g of gel. This is quite interesting, 
given that there was less polymer present in the former (1 g of gel). 
The drug loaded wafers appeared flakier and brittle in appearance 
compared to the blank wafers and might be related to the presence 
of BSA dispersed on the polymer strands within the wafer matrix. 
This could also explain the reason for the increased resistance to 
deformation (‘hardness’) of the BSA loaded wafers when compared 
with the blank wafers.
Mucoadhesion
Figure 5 shows that wafers prepared from pouring 2 and 3 g of gel 
had similar peak adhesive force (PAF) values. However, addition of 
BSA increased the PAF implying that adhesion was proportional to 
the amount of BSA present in the wafers up to 0.50 % w/w. This is vital 
as the functional performance of the wafer relate to how well and how 
long the wafer would adhere to the lining of the cheek and the overall 
release of the drug. Given the improved mucoadhesion behavior with 
BSA loading, it is expected that this will facilitate the absorption of 
macromolecules such as BSA via the buccal mucosa which will allow 
 
 
 
0.25 % w/w BSA 
0.50 % w/w BSA 
SA:Ch 4:1, 1g of gel 
SA:Ch 4:1, 2g of gel 
SA:Ch 4:1, 3g of gel 
SA:Ch 4:1, 5g of gel 
(a)
(b) 
Figure 3: (a) profiles for blank wafers prepared by pouring 1, 2, 3 and 5 g of 
the combined gel (SA: Ch 4:1) and (b) swelling profiles of drug loaded wafers 
prepared from pouring 3g of combined gel (SA: Ch 4:1).
SA:Ch 4:1, 1 g gel SA:Ch 4:1, 3 g gel
SA:Ch 4:1, 3 g gel, 0.25% w/w BSA
SA:Ch 4:1, 2 g gel
SA:Ch 4:1, 3 g gel, 0.50% w/w BSA
Figure 4: SEM images of optimised blank and drug loaded wafers obtained 
from SA: Ch 4:1 combined gels showing their morphological microstructure.
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improved bioavailability in the absence of a permeation enhancer 
as was the case in this study. This will however, require further 
investigations with an ex vivo or in vivo permeation study.
X-ray diffraction (XRD)
The diffractogram (Figure 6) shows a variety of peaks, relating 
to the nature of the compound. From Figure 6, it is evident that BSA 
and SA powder are amorphous in nature as shown by the broad peaks 
in the diffractogram. Ch shows a characteristic intense peak around 
23 two theta, which was also present in the blank and drug loaded 
wafers, suggesting some level of crystallinity. However, this could 
be related to other salts naturally present in Ch. Overall, it appears 
that the drug maintained its amorphous nature within the final 
wafers and implies it did not change its form during gel formulation 
in combination with SA as well as during freeze-drying. Stable 
amorphous forms are advantageous as they exhibit better solubility 
and therefore higher rates of dissolution which is expected to enhance 
drug release and subsequent absorption and bioavailability. However, 
though the amorphous drug was maintained, XRD cannot confirm 
protein conformational stability which will need to be confirmed 
using circular dichroism and mass spectrometry. 
In vitro drug dissolution study 
Figure 7a shows the calibration curve used to determine the 
amounts of BSA released from the wafers at each time point. The 
dissolution graphs (Figure 7b) show a sustained release of BSA over 
a two hour period. The rate of release was faster from the wafer 
Figure 5: Mucoadhesion profiles of optimised blank and drug loaded 
combined wafers showing PAF values.
Wafer, 0.25% w/w BSA
Wafer, 0.25% w/w BSA
Wafer 2 g gel
Wafer 3 g gel
Ch powder
BSA powder
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Figure 6: XRD diffractograms of pure starting materials, optimised blank 
wafers and drug loaded wafers.
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Figure 7: (a) Calibration curve of BSA (b) dissolution profiles of drug loaded 
wafers showing release of BSA from wafers containing different amounts of 
drug.
containing 0.25% w/w BSA and this formulation also showed a higher 
total % cumulative drug release after two hours compared to the 
formulation containing the higher amount of BSA with 66 % and 31% 
cumulative release respectively. These observations are interesting 
as the drug dissolution profiles directly mirror that observed in the 
hydration and swelling profiles of the two formulations. For swellable 
release systems such as SA and Ch, drug release is dependent on 
the rate of matrix hydration and subsequent diffusion of dissolved 
drug from the swollen polymer in the initial stages of drug release. 
Eventually, drug release is controlled by a combination of polymer 
swelling, drug diffusion and polymer erosion [36] which is possible in 
the current formulations.
Though the proposed composite buccal drug delivery formulation 
has potential for administration of macromolecules, there are some 
challenges in terms of eventual clinical applications. The current study 
used BSA as a model drug, however, use of therapeutic peptides such 
as insulin and larger proteins such as growth hormone are required 
in relatively small quantities which can be difficult to formulate and 
scale up. Furthermore, buccal delivery of macromolecules will not be 
rapid compared to parenteral injections and not easily administered 
for comatose patients and very young children. 
Conclusions
A lyophilized composite SA and Ch wafer loaded with BSA 
has been developed and optimized. The optimum wafer comprised 
SA and Ch in a 4:1 ratio respectively. The optimized formulations 
showed excellent functional mucosal characteristics including 
hardness, mucoadhesion, and swelling and in vitro drug release. The 
release of BSA which remained amorphous in the final wafer followed 
a sustained type release attributed to the rate of hydration and 
swelling. The optimized composite formulation offers a potentially 
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effective drug delivery system for buccal administration of large 
macromolecules.
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